ERBB2 and breast cancer: As Table 6 shows, the A/A genotype carriers of COMT rs165599 showed distinctly elevated scores on TBPM (4.94 ± 0.75 vs. 4.42 ± 0.71, p < 0.05) than G/G carriers in breast cancer patients with disparate status of HER2.